Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New cancer markers.

M J Duffy1

  • 1Department of Nuclear Medicine, St Vincent's Hospital, Dublin, Ireland.

Annals of Clinical Biochemistry
|September 1, 1989
PubMed
Summary
This summary is machine-generated.

New cancer markers like CA 19-9 and PSA aid in monitoring specific cancers. However, these markers are not entirely specific and their impact on survival needs further study.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells.

British journal of cancer·2025
Same author

A zinc phthalocyanine-benzoperylenetriimide conjugate for solvent dependent ultrafast energy vs. electron transfer.

Chemical communications (Cambridge, England)·2019
Same author

Trends in vitamin D supplement use in a general female and breast cancer population in Ireland: A repeated cross-sectional study.

PloS one·2018
Same author

Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM).

European journal of cancer (Oxford, England : 1990)·2017
Same author

Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?

International journal of cancer·2016
Same author

Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells.

British journal of cancer·2015
Same journal

Routine laboratory triage for NT-proBNP elevation may reflect cardiorenal frailty as much as heart failure specificity.

Annals of clinical biochemistry·2026
Same journal

From interpretable NT-proBNP prediction to equitable laboratory stewardship.

Annals of clinical biochemistry·2026
Same journal

Serum Sclerostin Levels in Children with Osteogenesis Imperfecta.

Annals of clinical biochemistry·2026
Same journal

Population-Specific HOMA-IR Reference Ranges in Iraq: Defining Insulin Sensitivity in a Middle Eastern Cohort.

Annals of clinical biochemistry·2026
Same journal

Optimizing Laboratory Quality with Sigma Metrics: Application of CLIA 2024 Total Allowable Error Guidelines.

Annals of clinical biochemistry·2026
Same journal

Suspected thermal amplitude of cryoglobulin likely more clinically significant than size detected: A case report.

Annals of clinical biochemistry·2026
See all related articles

Area of Science:

  • Oncology
  • Clinical Chemistry

Background:

  • Recent advancements have introduced novel cancer markers.
  • These markers offer potential clinical utility in diagnosing and monitoring malignancies.

Purpose of the Study:

  • To review the clinical utility of newly available cancer markers.
  • To assess the specificity and organ-specificity of these markers.
  • To evaluate their role in patient monitoring and survival outcomes.

Main Methods:

  • Literature review of recently developed cancer markers.
  • Analysis of clinical applications and limitations of each marker.
  • Evaluation of specificity, organ-specificity, and monitoring capabilities.

Main Results:

Related Experiment Videos

  • Key markers identified include CA 19-9 (pancreatic), CA 125 (ovarian), CA 15-3 (breast), PSA (prostate), PLAP (testicular), and NSE (lung).
  • None of the discussed markers are cancer-specific; only PSA is organ-specific to prostate tissue.
  • Primary utility lies in monitoring patients with established malignancies.

    • Conclusions:

    • New cancer markers are valuable for monitoring specific cancers but lack absolute specificity.
    • Further research is required to determine if routine use improves quality of life or survival.